Sepracor - Scientific Abstracts : LUNESTA® (eszopiclone)

1. Kocsis B, Shifflett L, Cogan S. Comparison of the effect of eszopiclone and other GABAA receptor modulators on hippocampal theta oscillations. Sleep 2009;32(Abstract Supplement):A16 (Abstract)

2. Krystal A, Cooper J, Schaefer K, Friedman M, Roth T. Weight changes in patients with primary insomnia following long-term eszopiclone treatment. Sleep 2009;32(Abstract Supplement):A280 (Abstract)

3. Morin C, Krystal A, McCall V, Schaefer K, Claus R, Wilson A, Friedman M, Roth T, Ancoli-Israel S. A responder analysis using the insomnia severity index in older adults treated for 12 weeks with eszopiclone 2mg or placebo. Sleep 2009;32(Abstract Supplement):A266 (Abstract)

4. Shah AA, Lettieri CJ, Holley AB, Roop SR, Kelly WF. Eszopiclone improves continuous positive airway pressure compliance: A prospective, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009;179:A1262 (Abstract)

5. Ancoli-Israel S, Krystal A, McCall WV, Schaefer K, Claus R, Rubens R, Roth T. A 12-week, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of eszopiclone in elderly outpatients with primary insomnia. World Psychiatry 2009;8(1):276 (Abstract)

6. Brunello N, Cooper J, Bettica P, Maier G, Nutt D. Differential pharmacological profiles of the GABAa receptor modulators zolpidem, zopiclone, eszopiclone, and (s)-desmethylzopiclone. World Psychiatry 2009;8(1):247 (Abstract)

7. Brunello N, Bettica P, Maier G, Nutt D. Pharmacokinetics of (s)-zopiclone and (s)-desmethylzopiclone following dosing with zopiclone and eszopiclone. World Psychaitry 2009;8(1):247 (Abstract)

8. Krystal A, Cooper J, Huang H, Schaefer K, Espie C. A comparison of sleep outcomes in patients with primary and comorbid insomnia treated with eszopiclone. World Psychiatry 2009;8(1):247 (Abstract)

9. Puertas J, Schaefer K, Huang H, Cooper J. Long-term eszopiclone treatment in patients with primary insomnia: a time by treatment interaction analysis. World Psychiatry 2009;8(1):247 (Abstract)

2008 LUNESTA (eszopiclone) Abstracts

1. Albanese M. Insomnia in dual diagnosis patients. Poster No. 7 in AAAP Annual Meeting and Symposium Program, p.41 (Abstract)

2. Collen JF, Lettieri C, Kelly W, Roop S. Clinical and polysomnographic predictors of short-term CPAP compliance. Chest 2008;134(4):s60003 (Abstract)

3. Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel T. the effect of nightly administration of eszopiclone in patients with insomnia and depression with high levels of anxiety (anxious depression). Poster 146 at The American College of Neuropsychopharmacology 2008, Scottsdale, AZ.

4. McCall WV, Krystal A, Fava M, Pollack M, Roach J, Wessel T, Schaefer K, Amato D. Individual rebound insomnia following eszopiclone discontinuation in patients with insomnia co-existing with MDD or GAD. New Research Abstracts of American Psychiatric Association Annual Meeting 2008: pp 318

5. Garlo KG, Crossin RA, Carskadon MA, LeBourgeois MK. Assessment of salivary dim light melatonin onset (DLMO) and reported sleep in preschool children. Sleep 2008;31(Suppl):A48 (Abstract)

6. Kumar S, Alam M, Rai S, McGinty D, Szymusiak R. Microdialysis perfusion of eszopiclone into the rat perifornical-lateral hypothalamus suppresses waking c-fos expression in hypocretin neurons. Sleep 2008;31(Suppl):A21 (Abstract)

7. LeBourgeois MK, Garlo KG, Carskadon MA. Salivary dim light melatonin onset (DLMO) and phase angles are associated with sleep initiation in preschool children. Sleep 2008;31(Suppl):A63-A64 (Abstract)

8. Lettieri CJ, Quast TN, Eliasson AH. Eszopiclone improves the quality of polysomnography: A prospective, randomized, placebo-controlled trial. Sleep 2008;31(Suppl):A201-A202 (Abstract)

9. McCall WV, Kimball J, Boggs N, Lasater B, Rosenquist PB. Correlation between polysomnography and actigraphy in detecting change in macro sleep variables during treatment of persons with both depression and insomnia. Sleep 2008;31(Suppl):A335-A336 (Abstract)

10. McCall WV, Kimball J, Boggs N, Lasater B, Rosenquist PB. Actigraphy as a component of screening for sleep apnea and periodic limb movements. Sleep 2008;31(Suppl):A336 (Abstract)

11. Moul DE, Cheng Y, Black BC, Miewald JM, Buysse DJ. Sleep latency data using the nocturnal sleep latency profile (NSLP): Proof of concept. Sleep 2008;31(Suppl):A258 (Abstract)

12. Nofzinger EA, Buysse D, Moul D, Hall M, Germain A, Price J. Eszopiclone reverses brain hyperarousal in insomnia: Evidence from [18F]-FDG PET. Sleep 2008;31(Suppl):A232 (Abstract)

13. Snedecor SJ, Botteman MF, Schaefer K, Barry N, Pickard A. Cost-effectiveness of eszopiclone for the treatment of adults with primary insomnia. Sleep 2008;31(Suppl):A246 (Abstract)

14. Xi M, Chase MH. Effects of eszopiclone on sleep and waking states in aged guinea pigs: Comparison with adult animals. Sleep 2008;31(Suppl):A28-A29 (Abstract)

15. Yang M, Morin C, Schaefer K, Wallenstein G. Defining the minimally important difference for the insomnia severity index. Sleep 2008;31(Suppl):A342 (Abstract)

16. Ye M, Garcia-Rill E. Potentiating effect of eszopiclone on GABAa responses of pedunculopontine (PPN) neurons. Sleep 2008;31(Suppl):A10 (Abstract)

17. Krystal A, Ancoli-Israel S, McCall WV, Schaefer K, Claus R, Roth T. A 12-week study of eszopiclone in elderly out-patients with primary insomnia: effects of treatment discontinuation. Consultant Pharmacist 2008;23(10):785 (Abstract)

18. Krystal A, Ancoli-Israel S, McCall WV, Schaefer K, Claus R, Roth T. The safety of eszopiclone in a 12-week study of elderly out-patients with primary insomnia. Consultant Pharmacist 2008;23(10):785 - 6 (Abstract)

19. Quast TM, Lettieri CJ, Eliasson AH, Andreada T. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: A prospective, randomized, placebo-controlled trial. AJRCCM 2008;177(Supplement)A804 (Abstract)

20. Bell C, Snedecor S, Botteman M, Schaefer K. Cost effectiveness of eszopiclone for the treatment of adults with primary insomnia in the US. International Journal of Neuropsychopharmacology 2008;11(1):305 (Abstract)

21. Cooper J, Pinette K, Montgomery S. Eszopiclone co-administered with escitalopram oxalate for insomnia co-existing with generalized anxiety disorder (GAD): a subgroup analysis. International Journal of Neuropsychopharmacology 2008;11(1):306 (Abstract)

22. Fava M. Addressing co-morbidities in insomnia. International Journal of Neuropsychopharmacology 2008;11(1):316 (Abstract)

23. Fava M, McCall W, Wessel T, Amato D, Paska W, Montgomery S, Roth T. Eszopiclone co-administered with fluoxetine for insomnia co-existing with major depressive disorder (MDD): a subgroup analysis. International Journal of Neuropsychopharmacology 2008;11(1):306 (Abstract)

24. Hajak G. Emerging treatments in insomnia. International Journal of Neuropsychopharmacology 2008;11(1):316 (Abstract)

25. Krystal A, Schaefer K, Rockett C, Fava M, Amato D, Roth T. Differential sleep effects of eszopiclone treatment and discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorders. International Journal of Neuropsychopharmacology 2008;11(1):306 (Abstract)

26. Montgomery S, Fava M, Krystal A, Wessel T, Amato D, Cooper K, McCall W. Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder (MDD) or generalized anxiety disorder. International Journal of Neuropsychopharmacology 2008;11(1):306 (Abstract)

27. Nutt D. Brain circuits and insomnia: role of GABA. International Journal of Neuropsychopharmacology 2008;11(1):315 (Abstract)

28. Paska W, Krystal A, Montgomery S. Efficacy of eszopiclone in the treatment of insomnia: a subset analysis by baseline wake time after sleep onset (WASO). International Journal of Neuropsychopharmacology 2008;11(1):307 (Abstract)

29. Brunello N, Bettica P, Amato D, Maier G, Nutt D. Pharmacokinetics of (S)-zopiclone and (S)-desmehylzopiclone following dosing with zopiclone and eszopiclone. European Neuropsychopharmacology 2008;18(Suppl 4):S581-S582 (Abstract)

30. Dijk D, Walsh J, Cooper J, Amato D, Schaefer K, Krystal A. Efficacy of eszopiclone and zolpidem in patients with primary insomnia: a responder analysis of objective sleep outcomes. European Neuropsychopharmacology 2008;18(Suppl 4):S577-S578 (Abstract)

31. Dijk D. Neural mechanisms of sleep and wakefulness: implications for insomnia treatment. European Neuropsychopharmacology 2008;18(Suppl 4):S603 (Abstract)

32. Garcia-Borreguero D. New concepts in the management of chronic insomnia. European Neuropsychopharmacology 2008;18(Suppl 4):S602-S603 (Abstract)

33. Krystal A. Addressing co-morbidities in insomnia. European Neuropsychopharmacology 2008;18(Suppl 4):S603-S604 (Abstract)

34. Krystal A, Ancoli-Israel S, McCall W, Schaefer K, Claus R, Rubens R, Roth T. The efficacy of 12 weeks of eszopiclone treatment in elderly patients with primary insomnia: effect on daytime function. European Neuropsychopharmacology 2008;18(Suppl 4):S517 (Abstract)

35. Krystal A, Ancoli-Israel S, McCall W, Schaefer K, Claus R, Rubens R, Roth T. A 12-week study of eszopiclone in elderly out-patients with primary insomnia: effects of treatment discontinuation. European Neuropsychopharmacology 2008;18(Suppl 4):S517 (Abstract)

36. Nofzinger E, Buysse DJ, Moul D, Hall M, Germain A, Price J. Eszopiclone reverses brain hyperarousal in insomnia patients: evidence from [18F]-FDG PET. European Neuropsychopharmacology 2008;18(Suppl 4):S263 (Abstract)

37. Nutt D. Brain circuits and insomnia: Role of GABA. European Neuropsychopharmacology 2008;18(Suppl 4):S603 (Abstract)

38. Chase MH, Xi M. Comparison of the effects of eszopiclone and zolpidem on delta power and NREM sleep in the adult guinea pig. European Psychiatry 2008;23:S359-S360 (Abstract)

39. Chase MH, Zhang JH, Fung SJ, Xi M, Sampogna S. Eszopiclone prevents apnea-induced programmed cell death (apoptosis) in the forebrain and brainstem of guinea pigs. European Psychiatry 2008;23:S359 (Abstract)

40. Fava M, Pollack M, Rubens R, Amato DA, Krystal A, Hayduk R, McCall WV. Evaluation of the HAMD-17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder. European Psychiatry 2008;23:S360 (Abstract)

2007 LUNESTA (eszopiclone) Abstracts

1. Bech P, Krystal A, Walsh J, Rubens R, Caron J, Wessel T, Amato D, Roth T, McCall WV, Fava M. Analysis of individual items of the Hamilton Depression Scale in a study of eszopiclone/fluoxetine co-therapy. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

2. Montgomery S, Kinrys G, Krystal A, McCall WV, Roth T, Rubens R, Schaefer K, Roach J, Huang H, Krishnan R, Pollack M. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

3. Wessel T, Caron J, Trick L, Rubens R, Roach J, Boyle J. The effect of eszopiclone 3mg on next day driving ability and cognitive and psychomotor function in patients with primary insomnia. Presented as a poster at the 15th European Congress of Psychiatry, March 17 - 21, 2007 (Abstract).

2006 LUNESTA (eszopiclone) Abstracts

1. Amato D, Wilson P, Schaefer K, Rubens R. The relationship between eszopiclone's effects on sleep and depression in patients with new onset Major Depressive Disorder (MDD) and insomnia. Presented at the 158th Annual Meeting of the American Psychiatric Association 2006, Toronto, Ontario. (Abstract).

2. Amato D, Wilson P, Schaefer K, Rubens R. The relationship between eszopiclone's effects on sleep and depression in patients with new onset Major Depressive Disorder (MDD) and insomnia: surrogate marker analysis. SLEEP 2006, 29:A239 (Abstract).

3. Caron J, Wessel T, Rosenberg R, Rubens R, Boccagno J, Anderson A, Walsh JK. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Presented at the Annual Meeting of the European Congress of Psychiatry, March 4 - 8, 2006, Nice, France. (Abstract).

4. Caron J, McCall V, Fava M, et al. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): analysis by age. Presented at the 31st Annual Meeting of the Japanese Society of Sleep Research 2006. (Abstract).

5. Doghramji PP, Winkelman J, Rubens R et al. Evaluation of patient satisfaction: Regimen of Eszopiclone Sleep Satisfaction Trial (RESST). SLEEP 2006, 29:A250 (Abstract).

6. Krystal A, Rubens R, Fava M, McCall V, Wessel T, Roth T. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): Effects following eszopiclone discontinuation. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

7. Krystal A, Walsh J, Rubens R et al. Efficacy and safety of six-months of nightly eszopiclone in patients with primary insomnia: a second long-term placebo-controlled study (Abstract). SLEEP 2006, 29, A249. (Abstract).

8. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Co-administration of eszopiclone and fluoxetine in MDD & insomnia: depression effects. Presented at the Annual Meeting of the European Congress of Psychiatry. March 4 - 8, 2006, Nice, France. (Abstract).

9. McCall V, Krystal A, Fava M et al. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): analysis by severity of insomnia (Abstract). SLEEP 2006, 29, A249. (Abstract).

10. McCall V, Krystal A, Rubens R et al. Two double-blind, placebo-controlled, 6-month trials of eszopiclone for insomnia: pooled analysis by race/ethnicity (Abstract). SLEEP 2006, 29, A249. (Abstract).

11. McCall V, Fava M, Wessel T, Rubens R, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): Analysis by age. 158th Annual Meeting of the American Psychiatric Association. 2006. (Abstract).

12. Roth T, Schnitzer T, Rubens R, Wessel T, Caron J, Amato D. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

13. Roth T, Schnitzer T, Niewoehner J et al. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Southern Sleep Society Annual Meeting 2006. (Abstract).

14. Rubens R, Roach J, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Presented at the Annual Meeting of the American Academy of Pain Medicine, February 22 - 25, 2006, San Diego, CA. (Abstract).

15. Schnitzer T, Rubens R, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. SLEEP 2006, 29, A238. (Abstract).

16. Soares CN, Joffe H, Rubens R, Amato D, Roach J, Caron J. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. 158th Annual Meeting of the American Psychiatric Association 2006. (Abstract).

17. Soares CN, Rubens R, Caron J et al. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. SLEEP 2006, 29, A239. (Abstract).

18. Soares CN, Joffe H, Skolly S et al. Eszopiclone treatment during menopausal transition: sleep effects, impact on menopausal symptoms and mood. Southern Sleep Society Annual Meeting . 2006. (Abstract).

19. Soares CN, Utian W, Rubens R, Amato D, Roach J, Cohen LS. Evaluation of eszopiclone 3 mg in the treatment of insomnia associated with the menopausal transition. Obstet Gynecol 2006, 107(4 Suppl):24S. (Abstract).

20. Wessel T, Roth T, Krystal A, Caron J, Amato D. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Presented at the Annual Meeting of the European Congress of Psychiatry, March 4 - 8, 2006, Nice, France. (Abstract).

21. Wessel T, Krystal A, Walsh J et al. Evaluation of the efficacy and safety of eszopiclone over six-months of treatment in patients with insomnia. 31st Annual Meeting of the Japanese Society of Sleep Research 2006. (Abstract).

2005 LUNESTA (eszopiclone) Abstracts

1. Allen SM, Rosenberg R, Rubens R. Four eszopiclone studies in elderly and non-elderly chronic insomniacs. Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

2. Amato D, McCall WV, Schaefer K, Rubens R. Effect of eszopiclone on sleep parameters that affect next day function. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR556 (Abstract).

3. Amato D, Buysse D, Wilson P. Trajectory analysis of treatment response across a twelve-month study of nightly eszopiclone in patients with chronic insomnia. SLEEP 2005; 28(Suppl):A239 (Abstract).

4. Anderson A, Maier G, Skolly S. Pharmacokinetic interaction of eszopiclone and ketoconazole in healthy subjects. Pharmacotherapy 2005, 25(3):474 (Abstract).

5. Anderson A, Skolly S, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin. International Pharmaceutical Abstracts 2005, 39:363e. (Abstract).

6. Anderson AJ, Maier G, Skolly SM. Pharmacokinetic interaction between eszopiclone and ketoconazole in healthy volunteers at steady state. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. Pg 100 (Abstract).

7. Anderson AJ, Roach J, Rosenberg R, Scharf M, Wilson P. Evaluation of eszopiclone in patients with obstructive sleep apnea. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. (Abstract).

8. Anderson AJ, McCall WV, Niewoehner J, Rubens R, Amato D. A pooled analysis of the safety and efficacy of eszopiclone in the treatment of primary insomnia in the elderly. In: Program and Abstracts of Senior Care Pharmacy 2005; American Society of Consultant Pharmacists 36th Annual Meeting, November 9 - 12, 2005, Boston, MA. Pg 93 (Abstract).

9. Botteman MF, Ozminkowski RJ, Wang S, Pashos C, Foley DJ, Schaefer K. Cost effectiveness of long-term treatment with eszopiclone 3 mg in adults with primary insomnia. Value in Health 2005; 8(3):323 (Abstract).

10. Buysse D, McCall WV, Rubens R, Wessel T, Wilson P, Caron J, Roth T. Adjunctive eszopiclone with fluoxetine for MDD and insomnia; sleep effects. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR558 (Abstract).

11. Buysse D, McCall WV, Roach J, Wessel T, Wilson P, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with Major Depressive Disorder (MDD): sleep effects. SLEEP 2005; 28(Suppl):A311 (Abstract).

12. Buysse D, McCall WV, Rubens R, Wessel T, Durrence HH, Wilson P, Allen S, Caron J, Roth T. Adjunctive eszopiclone with fluoxetine for MDD and insomnia: sleep effects. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

13. Corrigan M, McCall WV, Fava M, Rubens R, Wessel T, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder in insomnia: effects on sleep and depression. Neuropsychopharmacology 2005; 30(S1):S104 (Abstract).

14. Corrigan M, McCall WV, Fava M, Buysse DJ, Rubens R, Wessel T, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder and insomnia: Effects on sleep and depression. Presented at the Annual Meeting of the World Federation of Sleep Research and Sleep Medicine Societies 2005, New Delhi, India (Abstract).

15. Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD. Incidence of selected outcomes among matched cohorts of initiators of racemic zopiclone, temazepam, and zolpidem in the general practice research database. Pharmacoepidemiology and Drug Safety 2005, 14(S2):s22-s23. (Abstract).

16. Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD. Matched retrospective cohort study of breast cancer incidence among initiators of racemic zopiclone, temazepam, and zolpidem in the general practice research database. Pharmacoepidemiology and Drug Safety 2005, 14(S2):s162. (Abstract).

17. Erman MK, Walsh JK, Wessel T, Caron J, Amato D. A crossover study of eszopiclone in the treatment of primary insomnia. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR555 (Abstract).

18. Erman MK, Walsh JK, Wessel T, Caron J, Amato DA. A dose-response efficacy and safety study of eszopiclone in the treatment of primary insomnia. SLEEP 2005; 28(Suppl):A237 - A238 (Abstract).

19. Erman MK, Walsh JK, Durrence HH, Wessel T, Caron J, Amato D. A crossover study of eszopiclone in the treatment of primary insomnia. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

20. Fava M, Buysse D, Rubens R, Wessel T, Caron J, Roth T. Eszopiclone co-administrered with fluoxetine for insomnia associated with major depressive disorder (MDD): effects on sleep and depression. In: Program and Abstracts of New Clinical Drug Evaluation Unit Annual Meeting, June 6 - 9, 2005, Boca Raton, FL p. 308 (Abstract).

21. Krystal A, Rubens R, Fava M, McCall WV, Wessel T, Amato D, Caron J, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with major depressive disorder (MDD): effects following eszopiclone discontinuation. SLEEP 2005; 28(Suppl):A311 (Abstract).

22. Krystal A, Walsh JK, Roth T, Rubens R, Wilson P, Niewoehner J, Wessel T. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia. Pharmacotherapy 2005;25(10):1505 (Abstract).

23. Krystal A, Walsh J, Roth T, Rubens R, Wessel T. Efficacy and safety of six-months of nightly eszopiclone in patients with primary insomnia. Annals of Neurology 2005;(Suppl 9):S67 (Abstract).

24. Krystal A, Walsh JK, Roth T, Anderson A, Rubens R, Wilson Ph, Wessel T. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

25. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in MDD & insomnia: depression effects. In: Program and abstracts of the 158th Annual Meeting of the American Psychiatric Association, May 21 - 26, 2005, Atlanta, GA NR557 (Abstract).

26. McCall WV, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine for insomnia associated with Major Depressive Disorder (MDD): an analysis of the effects on depression. SLEEP 2005; 28(Suppl):A310 (Abstract).

27. McCall WV, Fava M, Buysse DJ, Rubens R, Wessel T, Caron J, Amato D, Anderson A, Roth T. Adjunctive eszopiclone and fluoxetine in Major Depressive Disorder and insomnia: effects on sleep and depression. Pharmacotherapy 2005; 25(10):1511 (Abstract).

28. McCall WV, Schaefer K, Fava M, Wessel T, Rubens R, Caron J, Amato D, Roth T. Adjunctive eszopiclone and fluoxetine in MDD and insomnia: depression effects. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

29. Niewoehner JW, Krystal A, Roach J, Caron J. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia: a subset analysis by baseline wake time after sleep onset (WASO). Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

30. Ozminkowski R, Lenhart G, Wang S, Barry N, Rubens R, Schaefer K, Anderson A. Using medical claims data and published literature to predict impact of formulary addition of a new anti-insomnia agent. Pharmacotherapy 2005, 25(3):471 (Abstract).

31. Ozminkowski R, Lenhart G, Wang S, Mucha L, Barry N, Schaefer K, Rubens R. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: a case study of insomnia treatment. Journal of Managed Care Pharmacy 2005; 11(3):284 (Abstract).

32. Ozminkowski R, Lenhart G, Wang S, Barry N, Schaefer K, Mucha L. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: a case study of insomnia treatment. SLEEP 2005; 28(Suppl):A239 (Abstract).

33. Ozminkowski R, Lenhart G, Wang S, Barry N, Schaefer K, Mucha L, Rubens R. Forecasting the impact of adding a new drug on formulary using medical claims data and clinical literature: a case study of insomnia treatment. Value in Health 2005: 8(3):323 (Abstract).

34. Roach J, Rosenberg R, Scharf M, Wilson P. Evaluation eszopiclone (ESZ) in patients with obstructive sleep apnea (OSA). Proceedings of the American Thoracic Society 2005; 2:A65 (Abstract).

35. Rosenberg R, Scharf M, Wilson P, Roach J. Evaluation of the safety and efficacy of eszopiclone in patients with obstructive sleep apnea. SLEEP 2005; 28(Suppl):A154 (Abstract).

36. Rubens R, Krystal A, Wessel T, Roth T, Caron J, Amato D. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia. Neurology 2005, 64(6)Suppl 1:A46 (Abstract).

37. Schnitzer T, Rubens R, Price J, Wessel T, Caron J, Amato D, Roth T. The effect of eszopiclone 3mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Arthritis and Rheumatism 2005;52(9):S352 (Abstract).

38. Skolly S, Erman MK, Wessel T. Consistency of patient-reported measures of efficacy and next day function of eszopiclone in adults with chronic insomnia treated with eszopiclone 3 mg. Presented at the Southern Sleep Society Annual Meeting, March 31 - April 3, 2005, New Orleans, LA (Abstract).

39. Soares C, Rubens R, Amato D, Roth T, Caron J, Skolly SM, Wessel T. Evaluation of eszopiclone 3mg in the treatment of insomnia associated with menopausal transition. Pharmacotherapy 2005; 25(10):1518 (Abstract).

40. Soares C, Rubens R, Amato D, Roth T, Caron J, Mariani R, Wessel T. Evaluation of eszopiclone 3 mg in the treatment of insomnia associated with menopausal transition. Presented at the 57th Institute on Psychiatric Services, October 5 - 9, 2005, San Diego, CA (Abstract).

41. Wessel T, Roth T, Krystal A, Caron J, Amato D. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Neurology 2005; 64(6)Suppl 1:A46 (Abstract).

42. Wessel T, Rubens R, Toth T, Krystal S, Walsh JK, Caron J, Amato D, Anderson AJ. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

43. Wessel T, Erman MK, Walsh JK, Caron J, Amato D, Anderson AJ. A dose-response efficacy and safety study of eszopiclone in the treatment of primary insomnia. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

44. Wessel T, Maier G, Rubens R, Amato D, Boccagno J, Anderson A. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopiclone: a comparison of healthy non-elderly and elderly adults. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).

45. Wessel T, Rosenberg R, Rubens R, Boccagno J, Anderson AJ, Walsh JK. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Presented at the 30th Annual Meeting of the Japanese Society of Sleep Research, Utsunomiya, Japan, June 30 - July 1, 2005 (Abstract).